# Estrella Immunopharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Estrella Immunopharma, Inc.). ## Overview Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. Its lead program, EB103, is an ARTEMIS®-based CD19-targeted T-cell therapy in Phase I/II testing, while EB104 and related combination work remain in early development. ## Products & services • EB103 CD19-targeted T-cell therapy • EB104 CD22-targeted T-cell therapy • STARLIGHT-1 Phase I/II clinical trial services • ARTEMIS®-licensed T-cell therapy development • EB103 + CF33-CD19t combination research - **Lead clinical program** (60%) — EB103 is the company's lead CD19-targeted T-cell therapy advancing through Phase I/II testing. - **Pipeline development** (25%) — EB104 and other preclinical/early-stage T-cell therapy efforts targeting CD22 and related indications. - **Collaborative research and combination therapy** (10%) — Work with Imugene and Eureka on combination approaches such as CF33-CD19t with EB103. - **Clinical operations and development services** (5%) — Trial execution, IND-enabling work, and outsourced development services supporting the pipeline. - EB103 CD19-targeted T-cell therapy - EB104 CD22-targeted T-cell therapy - STARLIGHT-1 Phase I/II clinical trial services - ARTEMIS®-licensed T-cell therapy development - EB103 + CF33-CD19t combination research ## Customers Estrella does not yet sell commercial products; its current 'customers' are effectively patients, investigators, clinical sites, and regulators involved in advancing its therapies. In the future, if approved, its therapies would be used by oncology treatment centers and prescribed by physicians for patients with hematologic cancers and potentially solid tumors. - **Clinical trial patients** (primary) — Patients enrolled in STARLIGHT-1 and related studies receive the investigational therapy to generate safety and efficacy data. - **Oncology treatment centers** (secondary) — Hospitals and cancer centers would be the channel for commercial use if EB103 or EB104 reach approval. - **Physicians and investigators** (primary) — Specialist clinicians select patients, run trials, and influence adoption of cell therapy protocols. - **Regulatory agencies** (primary) — The FDA and similar agencies review INDs and marketing applications that determine whether programs can proceed. - **Strategic development partners** (secondary) — Eureka and Imugene support platform access, services, and combination-development work. - Patients with blood cancers are the core target population for EB103 - Future oncology centers would administer approved cell therapies - Physicians and investigators drive trial enrollment and treatment adoption - Regulators such as the FDA determine whether programs can advance - Partners like Eureka provide development services and platform access ## Geography Estrella is headquartered in the United States and its development activity is centered around U.S. regulatory and clinical infrastructure. The company also established a wholly owned subsidiary in Hong Kong in late 2024, indicating a broader Asia-linked operating footprint, but it has not disclosed revenue geography because it has not generated revenue. - United States is the core operating and regulatory market - FDA clearance and U.S. clinical trials anchor development activity - Hong Kong subsidiary suggests future Asia-related structuring - No revenue geography disclosed because the company has no sales - Geographic exposure is mainly regulatory and clinical, not commercial ## Strategy Estrella's strategy is to advance its ARTEMIS®-licensed T-cell platform through clinical proof-of-concept, starting with EB103 and supported by EB104 and combination research. The company is also building the organizational and capital structure needed to fund development, manage public-company obligations, and preserve optionality for future commercialization or partnering. - **Complete clinical development of EB103** (short-term) — Clinical data are the main value driver for a pre-revenue cell therapy company and are needed for regulatory progress. - **Expand the pipeline beyond EB103** (medium-term) — A second asset and combination programs reduce single-asset risk and broaden the platform's commercial potential. - **Secure funding and operating flexibility** (short-term) — The company has no product revenue and depends on external capital to finance trials and corporate overhead. - Advance EB103 through STARLIGHT-1 to generate clinical data - Develop EB104 as a second CD22-targeted pipeline asset - Use Eureka's ARTEMIS® platform and services to accelerate execution - Pursue combination research with CF33-CD19t and Imugene - Raise capital to fund R&D and future commercialization readiness ## Risks Estrella is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and continued access to capital. The company also faces public-market and execution risks, including Nasdaq listing compliance, reliance on related-party services, and the possibility that its therapies never reach commercialization. - **Clinical development failure or delay** [high] — EB103 and EB104 are still in early-stage testing, so safety, efficacy, enrollment, or manufacturing issues could prevent approval. - **Financing risk** [high] — The company has no product revenue and expects to fund operations through external capital, which may be unavailable or dilutive. - **Nasdaq listing compliance** [high] — The company received a bid-price deficiency notice, and delisting would hurt liquidity and capital-raising ability. - **Related-party dependence** [medium] — Eureka performs key development services and owns the underlying platform license, creating concentration and negotiation risk. - **Regulatory approval risk** [high] — Even promising data may not translate into approval, and the company cannot monetize until regulators clear its products. - No revenue and no approved products create heavy dependence on financing - Clinical failure or delays would materially reduce program value - FDA or other regulatory setbacks could stop development - Nasdaq bid-price noncompliance could threaten listing and liquidity - Reliance on Eureka concentrates execution and counterparty risk ## Accounting The company is pre-revenue, so reported results are driven mainly by R&D accruals, stock-based compensation, and public-company overhead rather than sales recognition. Investors should watch related-party milestone liabilities, derivative accounting for financing instruments, and reverse-recapitalization presentation because these items can materially affect comparability and equity values. - **Revenue recognition** — No current sales; future revenue timing will be highly binary - **Related-party accruals and milestone obligations** — Affects R&D expense and accrued liabilities - **Stock-based compensation** — Impacts operating loss and equity dilution analysis - **Derivative liabilities** — Can affect earnings and balance-sheet volatility - **Reverse recapitalization accounting** — Limits comparability with pre-combination periods - No revenue recognition yet because no products are commercialized - R&D expense is dominated by outsourced clinical and lab service fees - Related-party milestone accruals affect liabilities and period expense - Stock-based compensation adds non-cash expense and can be material - Derivative liability accounting can create fair-value volatility --- *Last updated: 2026-04-28T20:05:26.221469+00:00*